Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPLE trial: Osimertinib strategy based on plasma T790M in EGFR-mutant NSCLC
2016-001834-82Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Progression-free survival rate at 18 months and Progression-free survival from randomization on osimertinib. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-001834-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001834-82.